| West Virginia Oncology Society |
Modified VISTA Regimen Easier on Elderly With Multiple Myeloma
Strategy Prevents GVHD in Haploidentical Transplants for Acute Leukemia
Bendamustine Outshines CHOP in Indolent Lymphoma
CML Drug Makes Comeback as Treatment for Imatinib-Resistant Disease
TO GET THIS AND MORE INFORMATION DIRECTLY FROM ASH…..CLICK HERE
* * * * * * * * * * * * * * * * *
PHYSICIAN INFO DIRECTLY FROM THE ASH WEBSITE
Gene Mutations Reveal Potential New Targets for Treating a Type of Non-Hodgkin Lymphoma (NIH)
Researchers have discovered genetic mutations that may contribute to the development of an aggressive
form of non-Hodgkin lymphoma.
2009 ASH Quick Reference: The Evaluation and Management of Heparin-Induced Thrombocytopenia
ASH has developed a pocket-sized Quick Reference guide based on The American College of Chest
Physicians Evidence-Based Clinical Practice Guideline on Antithrombotic and Thrombolytic Therapy.
- Melphalan is a better partner than thalidomide for induction bortezomib in a randomized phase III trial
with important implications for the treatment of elderly patients.
Strategy Prevents GVHD in Haploidentical Transplants for Acute Leukemia
- An adoptive immunotherapy strategy that uses T regulatory cells enables patients to receive a stem
cell transplant from a mismatched donor without developing GVHD.
Bendamustine Outshines CHOP in Indolent Lymphoma
- Bendamustine plus rituximab could oust the standard chemo regimen used with rituximab in the first-
line treatment of advanced lymphomas.
CML Drug Makes Comeback as Treatment for Imatinib-Resistant Disease
- Omacetaxine mepesuccinate is making a comeback as a potential therapy for chronic myeloid leukemia
with the T315I mutation.
TO GET THIS AND MORE INFORMATION DIRECTLY FROM ASH…..CLICK HERE
* * * * * * * * * * * * * * * * *
PHYSICIAN INFO DIRECTLY FROM THE ASH WEBSITE
Gene Mutations Reveal Potential New Targets for Treating a Type of Non-Hodgkin Lymphoma (NIH)
Researchers have discovered genetic mutations that may contribute to the development of an aggressive
form of non-Hodgkin lymphoma.
2009 ASH Quick Reference: The Evaluation and Management of Heparin-Induced Thrombocytopenia
ASH has developed a pocket-sized Quick Reference guide based on The American College of Chest
Physicians Evidence-Based Clinical Practice Guideline on Antithrombotic and Thrombolytic Therapy.
What's New. . . . .
| Conference News from the 51st Annual Meeting of the American Society of Hematology |
